Texas 2025 89th Regular

Texas House Bill HB5521 Introduced / Bill

Filed 03/14/2025

Download
.pdf .doc .html
                    89R9085 LRM-D
 By: Vasut H.B. No. 5521




 A BILL TO BE ENTITLED
 AN ACT
 relating to the possession and administration of an opioid
 antagonist by certain entities.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  Subchapter A, Chapter 773, Health and Safety
 Code, is amended by adding Section 773.018 to read as follows:
 Sec. 773.018.  POSSESSION AND ADMINISTRATION OF OPIOID
 ANTAGONIST. (a)  In this section, "live music venue" means a
 business with a space for live music and a primary revenue source of
 patron attendance to live music performances. The term includes a
 concert hall and indoor or outdoor stadium.
 (b)  This section applies to:
 (1)  an amusement park, as defined by Section 46.03,
 Penal Code;
 (2)  a live music venue;
 (3)  a sports venue, as defined by Section 504.151,
 Local Government Code; and
 (4)  subject to Subsection (c), other entities the
 executive commissioner by rule designates as an entity that
 benefits from the possession and administration of opioid
 antagonists.
 (c)  This section does not apply to a governmental entity.
 (d)  An entity subject to this section may adopt a policy
 regarding the maintenance, administration, and disposal of opioid
 antagonists.  The policy must authorize the administration of an
 opioid antagonist for a person reasonably believed to be
 experiencing an opioid overdose on the entity's premises only by an
 entity employee or volunteer who is authorized and trained to
 administer the opioid antagonist.
 (e)  The executive commissioner shall adopt rules regarding
 an entity's maintenance, administration, and disposal of opioid
 antagonists under this section.  The rules must establish:
 (1)  the number and dosages of the opioid antagonists
 available at each entity;
 (2)  the process for each entity to regularly verify
 its inventory of opioid antagonists for replacement of expired
 opioid antagonists; and
 (3)  the training required for an entity employee or
 volunteer to administer an opioid antagonist.
 (f)  Each entity that adopts a policy under Subsection (d)
 must have at least one entity employee or volunteer authorized and
 trained to administer an opioid antagonist present during all hours
 the entity is open to the public or the population the entity
 serves, as applicable.
 (g)  The entity's supply of opioid antagonists must:
 (1)  be stored in a secure location and in accordance
 with the manufacturer's instructions; and
 (2)  be easily accessible to an entity employee or
 volunteer who is authorized and trained to administer an opioid
 antagonist.
 (h)  Each entity that adopts a policy under Subsection (d) is
 responsible for training the entity's employees and volunteers in
 the administration of an opioid antagonist.  The training must:
 (1)  include information on:
 (A)  the signs and symptoms of an opioid overdose;
 (B)  the recommended opioid antagonist dosages
 for an adult and a child;
 (C)  the administration of an opioid antagonist;
 (D)  the implementation of any necessary
 emergency procedures after administration of an opioid antagonist;
 and
 (E)  the proper disposal of a used or expired
 opioid antagonist; and
 (2)  be completed annually in a formal training session
 or through online education.
 (i)  Each entity shall maintain records on the training
 completed by each entity employee and volunteer under this section.
 (j)  An entity, entity employee or volunteer, or other person
 who in good faith acts or fails to act as authorized under this
 section, including by administering an opioid antagonist as
 authorized in a policy adopted under this section, is immune from
 civil or criminal liability or disciplinary action resulting from
 that act or failure to act, including:
 (1)  supervising or delegating the administration of an
 opioid antagonist;
 (2)  possessing, maintaining, storing, or disposing of
 an opioid antagonist;
 (3)  administering, or assisting in the administration
 of, an opioid antagonist;
 (4)  providing training, consultation, or advice in the
 development, adoption, or implementation of policies, guidelines,
 or plans; or
 (5)  any other act authorized or required under this
 section.
 (k)  The immunities and protections provided by this section
 are in addition to other immunities or limitations of liability
 provided by law.
 (l)  Notwithstanding any other law, this section does not
 create a civil, criminal, or administrative cause of action or
 liability or create a standard of care, obligation, or duty that
 provides a basis for a cause of action for an act or omission under
 this section.  A cause of action does not arise from an act or
 omission described by this section.
 (m)  An act or failure to act by an entity employee or
 volunteer under this section, including an act or failure to act
 under related entity policies and procedures, is the exercise of
 judgment or discretion on the part of the entity employee or
 volunteer and is not considered to be a ministerial act for purposes
 of liability of the entity.
 SECTION 2.  This Act takes effect September 1, 2025.